Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Pathology & Oncology Research
Published in: Pathology & Oncology Research 3/2012

01-07-2012 | Research

Angiogenesis and Survival in Patients with Myelodysplastic Syndrome

Authors: Aleksandar Savic, Vesna Cemerikic-Martinovic, Sinisa Dovat, Nebojsa Rajic, Ivana Urosevic, Borivoj Sekulic, Vanja Kvrgic, Stevan Popovic

Published in: Pathology & Oncology Research | Issue 3/2012

Login to get access

Abstract

Angiogenesis has been implicated in the pathogenesis and prognosis of myelodysplastic syndrome (MDS). In this study, we investigated the relationship between microvessel density (MVD), vascular endothelial growth factor (VEGF) expression, common morphological and clinical factors, and survival in patients with MDS. We examined the MVD of paraffin-embedded bone marrow sections from 70 MDS patients and 31 controls. VEGF expression was determined in 50 patients and 20 controls. The median MVD in MDS patients was significantly higher than that in controls (p = 0.025), whereas there was no difference in VEGF expression between MDS patients and controls. In univariate analysis, increased MVD was associated with a shorter survival time (p = 0.023). However, in multivariate analysis, MVD was not an independent predictor of survival. The VEGF expression did not influence survival in univariate analysis. Survival was independently influenced by platelet count (p = 0.0073), cytogenetic risk category (p = 0.022), and transfusion dependence (p = 0.0073). Neither MVD nor VEGF expression were predictors for progression to acute myeloid leukemia in univariate analysis. Progression to acute myeloid leukemia was independently influenced only by the cytogenetic risk category (p = 0.022). This study confirmed increased MVD in MDS. It does not support an independent prognostic role of angiogenesis in MDS.
Literature
1.
Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid, and other disease. Nat Med 1:27–31PubMedCrossRef
2.
3.
Padro T, Ruiz S, Bieker R et al (2000) Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood 95:2637–2644PubMed
4.
Hussong JW, Rodgers JM, Shami PJ (2000) Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood 95:309–313PubMed
5.
Lundberg LG, Lerner R, Sundelin P et al (2000) Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity. Am J Pathol 157:15–19PubMedCrossRef
6.
Mesa RA, Hanson CA, Rajkumar SV et al (2000) Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia. Blood 96:3374–3380PubMed
7.
Peterson L, Kini AR (2001) Angiogenesis is increased in B-cell chronic lymphocytic leukemia. Blood 97:2529PubMedCrossRef
8.
Rajkumar SV, Leong T, Roche PC et al (2000) Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res 6:3111–3116PubMed
9.
Aguayo A, Kantarjian H, Manshouri T et al (2000) Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 96:2240–2245PubMed
10.
Pruneri G, Bertolini F, Soligo D et al (1999) Angiogenesis in myelodysplastic syndromes. Br J Cancer 81:1398–1401PubMedCrossRef
11.
Korkolopoulou P, Apostolidou E, Pavlopoulos PM et al (2001) Prognostic evaluation of the microvascular network in myelodysplastic syndromes. Leukemia 15:1369–1376PubMedCrossRef
12.
Lundberg LG, Hellstrom-Lindberg E, Kanter-Lewensohn L et al (2006) Angiogenesis in relation to clinical stage, apoptosis and prognostic score in myelodysplastic syndromes. Leuk Res 30:247–253PubMedCrossRef
13.
Alexandrakis MG, Passam FH, Pappa CA et al (2005) Relation between bone marrow angiogenesis and serum levels of angiogenin in patients with myelodysplastic syndromes. Leuk Res 29:41–46PubMedCrossRef
14.
Gale NW, Yancopoulos GD (1999) Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. Genes Dev 13:1055–1066PubMedCrossRef
15.
Bellamy WT, Richter L, Sirjani D et al (2001) Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood 97:1427–1434PubMedCrossRef
16.
Wimazal F, Krauth MT, Vales A et al (2006) Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the bone marrow in patients with myelodysplastic syndromes: correlation between VEGF expression and the FAB category. Leuk Lymphoma 47:451–460PubMedCrossRef
17.
Bennett JM, Catovsky D, Daniel MT et al (1982) Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189–199PubMed
18.
Brunning RD, Orazi A, Germing U et al (2008) Myelodysplastic syndromes/Neoplasms, overview. In: Swerdlow SH, Campo E, Harris NL et al (eds) WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. IARC, Lyon, pp 88–93
19.
Greenberg P, Cox C, LeBeau MM et al (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079–2088PubMed
20.
Thiele J, Kvasnicka HM, Facchetti F et al (2005) European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 90:1128–1132PubMed
21.
Tricot G, De Wolf-Peeters C, Vlietinck R et al (1984) Bone marrow histology in myelodysplastic syndromes. II. Prognostic value of abnormal localization of immature precursors in MDS. Br J Haematol 58:217–225PubMedCrossRef
22.
Perez-Atayde AR, Sallan SE, Tedrow U et al (1997) Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol 150:815–821PubMed
23.
Keith T, Araki Y, Ohyagi M et al (2007) Regulation of angiogenesis in the bone marrow of myelodysplastic syndromes transforming to overt leukaemia. Br J Haematol 137:206–215PubMedCrossRef
24.
Malcovati L, Germing U, Kuendgen A et al (2007) Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 25:3503–3510PubMedCrossRef
25.
Verstovsek S, Estey E, Manshouri T et al (2002) Clinical relevance of vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukaemia and myelodysplastic syndrome. Br J Haematol 118:151–156PubMedCrossRef
26.
Gabrilove J (2001) Angiogenic growth factors: autocrine and paracrine regulation of survival in hematologic malignancies. Oncologist 6(Suppl 5):4–7PubMedCrossRef
27.
Dias S, Hattori K, Zhu Z et al (2000) Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J Clin Invest 106:511–521PubMedCrossRef
28.
Padro T, Bieker R, Ruiz S et al (2002) Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR(VEGFR-2) in the bone marrow of patients with acute myeloid leukemia. Leukemia 16:1302–1310PubMedCrossRef
29.
Germing U, Hildebrandt B, Pfeilstöcker M et al (2005) Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS). Leukemia 19:2223–2231PubMedCrossRef
30.
Sperr WR, Wimazal F, Kundi M et al (2001) Survival analysis and AML development in patients with de novo myelodysplastic syndromes: comparison of six different prognostic scoring systems. Ann Hematol 80:272–277PubMedCrossRef
31.
Horny HP, Sotlar K, Valent P (2007) Diagnostic value of histology and immunohistochemistry in myelodysplastic syndromes. Leuk Res 31:1609–1616PubMedCrossRef
32.
Valent P, Horny HP, Bennett JM et al (2007) Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res 31:727–736PubMedCrossRef
33.
Patsouris E, Katsarou O, Korkolopoulou P et al (2004) Increased microvascular network in bone marrow of HIV-positive haemophilic patients. HIV Med 5:18–25PubMedCrossRef
34.
List A, Dewald G, Bennett J et al (2006) Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 355:1456–1465PubMedCrossRef
35.
Raza A, Reeves JA, Feldman EJ et al (2008) Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 111:86–93PubMedCrossRef
36.
Musto P (2004) Thalidomide therapy for myelodysplastic syndromes: current status and future perspectives. Leuk Res 28:325–332PubMedCrossRef
37.
Giles FJ, Stopeck AT, Silverman LR et al (2003) SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood 102:795–801PubMedCrossRef
38.
Giles FJ, Bellamy WT, Estrov Z et al (2006) The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Leuk Res 30:801–811PubMedCrossRef
39.
Oh ST, Gotlib J (2008) Antiangiogenic therapy in myelodysplastic syndromes: is there a role? Curr Hematol Malig Rep 3:10–18PubMedCrossRef
Metadata
Title
Angiogenesis and Survival in Patients with Myelodysplastic Syndrome
Authors
Aleksandar Savic
Vesna Cemerikic-Martinovic
Sinisa Dovat
Nebojsa Rajic
Ivana Urosevic
Borivoj Sekulic
Vanja Kvrgic
Stevan Popovic
Publication date
01-07-2012
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 3/2012
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-012-9495-y

Other articles of this Issue 3/2012

Pathology & Oncology Research 3/2012 Go to the issue

Research

Upregulation of a Disintegrin and Metalloprotease 8 Influences Tumor Metastasis and Prognosis in Patients with Osteosarcoma

Case Report

Hodgkin’s Lymphoma Developed after Autologous Stem Cell Transplantation for Multiple Myeloma

Report

Uncommon Late Relapse of Angioimmunoblastic T-Cell Lymphoma after 16-Year Remission Period

Research

ABVD as the Treatment Option in Advanced Hodgkin’s Lymphoma Patients Older than 45 Years

Research

D-Dimer as a Potential Prognostic Marker

Research

Expression of Tight Junction Molecules in Breast Carcinomas Analysed by Array PCR and Immunohistochemistry
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits